Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 4/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24021249 | 0.85 | TLR7 (0.51) | TLR7AKR1C3AKR1C2PPARDPPARA | |
| SCHEMBL20222980 | 0.82 | TLR7 (0.47) | TLR7AKR1C3AKR1C2MEN1HTT | |
| SCHEMBL24021196 | 0.82 | TLR7 (0.49) | TLR7AKR1C3AKR1C2MEN1HTT | |
| SCHEMBL24021217 | 0.81 | TLR7 (0.51) | TLR7AKR1C3AKR1C2PPARDPPARA | |
| SCHEMBL24021218 | 0.80 | TLR7 (0.50) | TLR7AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL24021262 | 0.79 | ATM (0.51) | ATML3MBTL1MEN1HTTKMT2A | |
| SCHEMBL24021172 | 0.79 | L3MBTL1 (0.43) | ATML3MBTL1MEN1HTTKMT2A | |
| SCHEMBL602723 | 0.78 | CA12 (0.52) | L3MBTL1AKR1C3AKR1C2KMT2AHSD17B10 | |
| SCHEMBL24021242 | 0.77 | APP (0.39) | ATML3MBTL1TLR7AKR1C3AKR1C2 | |
| SCHEMBL3753644 | 0.77 | AKR1C3 (0.49) | L3MBTL1TLR7AKR1C3AKR1C2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548478-B1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10786502-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10786502-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | ATM 1393/4885L3MBTL1 3141/4885TLR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.